Purdue Pharma owners willing to pay up to $6bn to settle opioid suits

The offer was detailed in a report filed on Friday in US bankruptcy court by a federal mediator who asked the court to let her have until the end of the month to broker a new settlement.

Under the latest proposal, the Sacklers would contribute between $5.5bn and $6bn, an increase from the $4.3bn they had agreed to in the original bankruptcy settlement.

The last of the money would not be paid out for 18 years, and the exact amount would depend on how much the family would make from selling its international drug companies.

The additional money would have to be used to combat a crisis that has been linked to more than 500,000 deaths in the US over the past two decades. Part of it would be controlled by the eight states, joined by the District of Columbia, that objected to the original settlement last year even when other states agreed.

In exchange, members of the family would be shielded from current and future opioid-related lawsuits. That protection was contained in the original settlement but prompted the objecting states to file an appeal that ultimately succeeded, leading to the current negotiations.

The objecting states said the earlier amount of $4.5bn did not go far enough to hold accountable members of a family that made billions from the sale of OxyContin.

Advocates for opioid victims and their families were concerned about where the additional money would go.